Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2003 Nov;58(11):942–946. doi: 10.1136/thorax.58.11.942

Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD

S Culpitt 1, D Rogers 1, P Fenwick 1, P Shah 1, C De Matos 1, R Russell 1, P Barnes 1, L Donnelly 1
PMCID: PMC1746526  PMID: 14586044

Abstract

Background: The pathophysiology of chronic obstructive pulmonary disease (COPD) features pulmonary inflammation with a predominant alveolar macrophage involvement. Bronchoalveolar macrophages from patients with COPD release increased amounts of inflammatory cytokines in vitro, an effect that is not inhibited by the glucocorticosteroid dexamethasone. Resveratrol (3,5,4'-trihydroxystilbene) is a component of red wine extract that has anti-inflammatory and antioxidant properties. A study was undertaken to determine whether or not resveratrol would inhibit cytokine release in vitro by alveolar macrophages from patients with COPD.

Methods: Alveolar macrophages were isolated from bronchoalveolar lavage (BAL) fluid from cigarette smokers and from patients with COPD (n=15 per group). The macrophages were stimulated with either interleukin (IL)-1ß or cigarette smoke media (CSM) to release IL-8 and granulocyte macrophage-colony stimulating factor (GM-CSF). The effect of resveratrol was examined on both basal and stimulated cytokine release.

Results: Resveratrol inhibited basal release of IL-8 in smokers and patients with COPD by 94% and 88% respectively, and inhibited GM-CSF release by 79% and 76% respectively. Resveratrol also inhibited stimulated cytokine release. Resveratrol reduced IL-1ß stimulated IL-8 and GM-CSF release in both smokers and COPD patients to below basal levels. In addition, resveratrol inhibited CSM stimulated IL-8 release by 61% and 51% respectively in smokers and COPD patients, and inhibited GM-CSF release by 49% for both subject groups.

Conclusions: Resveratrol inhibits inflammatory cytokine release from alveolar macrophages in COPD. Resveratrol or similar compounds may be effective pharmacotherapy for macrophage pathophysiology in COPD.

Full Text

The Full Text of this article is available as a PDF (267.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abboud R. T., Ofulue A. F., Sansores R. H., Muller N. L. Relationship of alveolar macrophage plasminogen activator and elastase activities to lung function and CT evidence of emphysema. Chest. 1998 May;113(5):1257–1263. doi: 10.1378/chest.113.5.1257. [DOI] [PubMed] [Google Scholar]
  2. Barnes P. J. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):342–344. doi: 10.1164/ajrccm.161.2.16125_2. [DOI] [PubMed] [Google Scholar]
  3. Barnes Peter J. New concepts in chronic obstructive pulmonary disease. Annu Rev Med. 2001 Dec 3;54:113–129. doi: 10.1146/annurev.med.54.101601.152209. [DOI] [PubMed] [Google Scholar]
  4. Bhat Krishna P. L., Pezzuto John M. Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci. 2002 May;957:210–229. doi: 10.1111/j.1749-6632.2002.tb02918.x. [DOI] [PubMed] [Google Scholar]
  5. Calverley P. M. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):341–344. doi: 10.1164/ajrccm.161.2.16125_1. [DOI] [PubMed] [Google Scholar]
  6. Casper R. F., Quesne M., Rogers I. M., Shirota T., Jolivet A., Milgrom E., Savouret J. F. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol. 1999 Oct;56(4):784–790. [PubMed] [Google Scholar]
  7. Culpitt S. V., Rogers D. F. Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2000 Jul;1(5):1007–1020. doi: 10.1517/14656566.1.5.1007. [DOI] [PubMed] [Google Scholar]
  8. Culpitt Sarah V., Rogers Duncan F., Shah Pallav, De Matos Carmen, Russell Richard E. K., Donnelly Louise E., Barnes Peter J. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002 Sep 17;167(1):24–31. doi: 10.1164/rccm.200204-298OC. [DOI] [PubMed] [Google Scholar]
  9. Donnelly Louise E., Rogers Duncan F. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs. 2003;63(19):1973–1998. doi: 10.2165/00003495-200363190-00002. [DOI] [PubMed] [Google Scholar]
  10. Dubar V., Gosset P., Aerts C., Voisin C., Wallaert B., Tonnel A. B. In vitro acute effects of tobacco smoke on tumor necrosis factor alpha and interleukin-6 production by alveolar macrophages. Exp Lung Res. 1993 May-Jun;19(3):345–359. doi: 10.3109/01902149309064351. [DOI] [PubMed] [Google Scholar]
  11. Ekberg-Jansson A., Andersson B., Bake B., Boijsen M., Enanden I., Rosengren A., Skoogh B. E., Tylén U., Venge P., Löfdahl C. G. Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(CO) and to emphysematous changes on high resolution CT. Respir Med. 2001 May;95(5):363–373. doi: 10.1053/rmed.2001.1050. [DOI] [PubMed] [Google Scholar]
  12. Fantone J. C., Ward P. A. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol. 1982 Jun;107(3):395–418. [PMC free article] [PubMed] [Google Scholar]
  13. Frémont L. Biological effects of resveratrol. Life Sci. 2000 Jan 14;66(8):663–673. doi: 10.1016/s0024-3205(99)00410-5. [DOI] [PubMed] [Google Scholar]
  14. Gao X., Xu Y. X., Janakiraman N., Chapman R. A., Gautam S. C. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol. 2001 Nov 1;62(9):1299–1308. doi: 10.1016/s0006-2952(01)00775-4. [DOI] [PubMed] [Google Scholar]
  15. Izeboud C. A., Mocking J. A., Monshouwer M., van Miert A. S., Witkamp R. F. Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release. J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):191–202. doi: 10.3109/10799899909036645. [DOI] [PubMed] [Google Scholar]
  16. Jang M., Pezzuto J. M. Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res. 1999;25(2-3):65–77. [PubMed] [Google Scholar]
  17. Jeffery P. K. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest. 2000 May;117(5 Suppl 1):251S–260S. doi: 10.1378/chest.117.5_suppl_1.251s. [DOI] [PubMed] [Google Scholar]
  18. Linden M., Rasmussen J. B., Piitulainen E., Tunek A., Larson M., Tegner H., Venge P., Laitinen L. A., Brattsand R. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis. 1993 Nov;148(5):1226–1232. doi: 10.1164/ajrccm/148.5.1226. [DOI] [PubMed] [Google Scholar]
  19. Lohmann-Matthes M. L., Steinmüller C., Franke-Ullmann G. Pulmonary macrophages. Eur Respir J. 1994 Sep;7(9):1678–1689. [PubMed] [Google Scholar]
  20. Manna S. K., Mukhopadhyay A., Aggarwal B. B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol. 2000 Jun 15;164(12):6509–6519. doi: 10.4049/jimmunol.164.12.6509. [DOI] [PubMed] [Google Scholar]
  21. Martinez J., Moreno J. J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol. 2000 Apr 1;59(7):865–870. doi: 10.1016/s0006-2952(99)00380-9. [DOI] [PubMed] [Google Scholar]
  22. Mio T., Romberger D. J., Thompson A. B., Robbins R. A., Heires A., Rennard S. I. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir Crit Care Med. 1997 May;155(5):1770–1776. doi: 10.1164/ajrccm.155.5.9154890. [DOI] [PubMed] [Google Scholar]
  23. Randerath E., Danna T. F., Randerath K. DNA damage induced by cigarette smoke condensate in vitro as assayed by 32P-postlabeling. Comparison with cigarette smoke-associated DNA adduct profiles in vivo. Mutat Res. 1992 Jul;268(1):139–153. doi: 10.1016/0027-5107(92)90091-f. [DOI] [PubMed] [Google Scholar]
  24. Russell Richard E. K., Culpitt Sarah V., DeMatos Carmen, Donnelly Louise, Smith Michael, Wiggins John, Barnes Peter J. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2002 May;26(5):602–609. doi: 10.1165/ajrcmb.26.5.4685. [DOI] [PubMed] [Google Scholar]
  25. Scanlon P. D., Connett J. E., Waller L. A., Altose M. D., Bailey W. C., Buist A. S., Tashkin D. P., Lung Health Study Research Group Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):381–390. doi: 10.1164/ajrccm.161.2.9901044. [DOI] [PubMed] [Google Scholar]
  26. Sgambato A., Ardito R., Faraglia B., Boninsegna A., Wolf F. I., Cittadini A. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res. 2001 Sep 20;496(1-2):171–180. doi: 10.1016/s1383-5718(01)00232-7. [DOI] [PubMed] [Google Scholar]
  27. Soleas G. J., Diamandis E. P., Goldberg D. M. The world of resveratrol. Adv Exp Med Biol. 2001;492:159–182. doi: 10.1007/978-1-4615-1283-7_13. [DOI] [PubMed] [Google Scholar]
  28. Surh Y. J., Chun K. S., Cha H. H., Han S. S., Keum Y. S., Park K. K., Lee S. S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res. 2001 Sep 1;480-481:243–268. doi: 10.1016/s0027-5107(01)00183-x. [DOI] [PubMed] [Google Scholar]
  29. Wieder T., Prokop A., Bagci B., Essmann F., Bernicke D., Schulze-Osthoff K., Dörken B., Schmalz H. G., Daniel P. T., Henze G. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia. 2001 Nov;15(11):1735–1742. doi: 10.1038/sj.leu.2402284. [DOI] [PubMed] [Google Scholar]
  30. Wirtz H. R., Schmidt M. Acute influence of cigarette smoke on secretion of pulmonary surfactant in rat alveolar type II cells in culture. Eur Respir J. 1996 Jan;9(1):24–32. doi: 10.1183/09031936.96.09010024. [DOI] [PubMed] [Google Scholar]
  31. Zhong M., Cheng G. F., Wang W. J., Guo Y., Zhu X. Y., Zhang J. T. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine. 1999 May;6(2):79–84. doi: 10.1016/S0944-7113(99)80039-7. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES